Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xenetic Biosciences (XBIO)
NASDAQ:XBIO
RESEARCH TOOLSreports
Holding XBIO?
Track your performance easily
XBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.87 - $5.97
Previous Close$4.08
Volume12.26K
Average Volume (3M)4.85K
Market Cap
$6.29M
Enterprise Value-$1.54M
Total Cash (Recent Filing)$7.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 09, 2024EPS Estimate
-$0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.92
Shares Outstanding1,540,684
10 Day Avg. Volume3,418
30 Day Avg. Volume4,852
Standard Deviation0.33
R-Squared0.14
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.79
Price to Sales (P/S)10.23
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.65
Enterprise Value/Gross Profit-0.61
Enterprise Value/Ebitda0.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Xenetic Biosciences News
PremiumCompany Announcements
Xenetic Biosciences Expands Collaboration for Cancer Treatment
PremiumCompany Announcements
Xenetic Biosciences Announces Executive Leadership RestructuringBulls Say, Bears Say
Bulls Say
New InitiativesXenetic continues its focus on its DNase 1 based pipeline with plans to initiate Phase 1 studies in pancreatic carcinoma and locally advanced or metastatic solid tumors.
Research CollaborationThe newly announced agreement seeks to evaluate the systemic DNase program in combination with existing therapies for the potential treatment of solid tumor indications, including pancreatic carcinoma.
Strategic PartnershipXenetic announced it has entered into a research and development collaboration with The Scripps Institute to advance the company’s systemic DNase program.
Bears Say
Cash ReservesThe company ended the quarter with $9 million in cash, highlighting potential financial risks.
Financial PerformanceXenetic posted EPS of ($0.76) and ($2.71), indicating financial strains.
FundingAdditional funding will need to be secured to bring this study to fruition.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $2.87 and its highest was $5.97 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Currently, no data Available
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is Aug 09, 2024 which is 93 days ago.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on May 10, 2024. The company reported -$0.78 earnings per share for the quarter, the consensus estimate of -$0.78 by $0.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate is -$0.83.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 1,540,684 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.78 in its last earnings report, expectations of -$0.78. Following the earnings report the stock price went down -3.465%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
---
Xenetic Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.85%
12-Months-Change
Fundamentals
Return on Equity
-41.54%
Trailing 12-Months
Asset Growth
-31.51%
Trailing 12-Months
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The XCART has the potential to fuel a robust pipeline of therapeutic assets targeting oncology indications. Additionally, Xenetic is leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. The PolyXen has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. Xenetic Biosciences was founded on and is headquartered in Framingham, MA.
---
XBIO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---